Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.

Adrienne G Waks Anwesha ChaudhuryNadia SolovieffLaia ParéDébora MartinezNuria ChicOlga Martínez-SáezFara Brasó-MaristanyAgnes LteifTetiana TaranNaveen BabbarFei Su

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

In this retrospective exploratory analysis of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer, each intrinsic subtype exhibited a consistent PFS benefit with RIB, except for basal-like.

Keyphrases

epidermal growth factor receptor
phase iii
tyrosine kinase
open label
advanced non small cell lung cancer
clinical trial
endothelial cells
double blind
induced pluripotent stem cells
placebo controlled
phase ii
cross sectional
pluripotent stem cells
case control
randomized controlled trial
study protocol